Furthermore, certain biologic therapies (Secukinumab, an anti-IL17 monoclonal antibody) utilized in psoriasis may predispose patients to a subsequent development of IBD [22,23,24]. This evidence concerns the gene IL17A and inflammatory bowel disease.